Supernus Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Supernus Pharmaceuticals, Inc.‘s stocks are currently a part of 169 hedge funds’ portfolios, which represents 49.75% of the total amount of its stocks outstanding. This makes up a total of 30.68M shares of Supernus Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -45.02% or -25.13M shares fewer. As for the holding position changes, 35.5% (60) of current hedge fund investors increased the number of shares held, 38.46% (65) of current holders sold a part of the shares held, and 10.06% (17) closed the holdings completely. 16 hedge funds are new holders of Supernus Pharmaceuticals, Inc. stock in Q1 2023, it is 9.47% of total holders.
Hedge funds holding Supernus Pharmaceuticals (Q2 2018 – Q1 2023)
| Q2 2018 | 317 |
|---|---|
| Q3 2018 | 283 |
| Q4 2018 | 272 |
| Q1 2019 | 288 |
| Q2 2019 | 270 |
| Q3 2019 | 240 |
| Q4 2019 | 232 |
| Q1 2020 | 204 |
| Q2 2020 | 216 |
| Q3 2020 | 207 |
| Q4 2020 | 221 |
| Q1 2021 | 218 |
| Q2 2021 | 221 |
| Q3 2021 | 216 |
| Q4 2021 | 227 |
| Q1 2022 | 222 |
| Q2 2022 | 217 |
| Q3 2022 | 237 |
| Q4 2022 | 255 |
| Q1 2023 | 169 |
Hedge funds changes in Supernus Pharmaceuticals positions (Q2 2018 – Q1 2023)
| Q2 2018 | 46 | 112 | 119 | 38 | 2 |
|---|---|---|---|---|---|
| Q3 2018 | 29 | 96 | 113 | 61 | -16 |
| Q4 2018 | 35 | 105 | 92 | 47 | -7 |
| Q1 2019 | 43 | 118 | 77 | 25 | 25 |
| Q2 2019 | 34 | 92 | 98 | 48 | -2 |
| Q3 2019 | 21 | 86 | 91 | 49 | -7 |
| Q4 2019 | 33 | 78 | 88 | 34 | -1 |
| Q1 2020 | 24 | 65 | 84 | 48 | -17 |
| Q2 2020 | 40 | 81 | 67 | 27 | 1 |
| Q3 2020 | 22 | 80 | 71 | 31 | 3 |
| Q4 2020 | 37 | 74 | 83 | 22 | 5 |
| Q1 2021 | 34 | 75 | 74 | 33 | 2 |
| Q2 2021 | 31 | 73 | 82 | 27 | 8 |
| Q3 2021 | 31 | 79 | 74 | 33 | -1 |
| Q4 2021 | 40 | 89 | 66 | 27 | 5 |
| Q1 2022 | 31 | 68 | 99 | 33 | -9 |
| Q2 2022 | 26 | 85 | 79 | 27 | 0 |
| Q3 2022 | 39 | 90 | 75 | 21 | 12 |
| Q4 2022 | 39 | 91 | 88 | 17 | 20 |
| Q1 2023 | 16 | 60 | 65 | 17 | 11 |
Hedge funds changes in Supernus Pharmaceuticals stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 16,675,000 | 33,216,000 |
|---|---|---|
| Q3 2018 | 13,005,000 | 18,241,000 |
| Q4 2018 | 7,409,000 | 11,066,000 |
| Q1 2019 | 8,254,000 | 15,056,000 |
| Q2 2019 | 11,529,000 | 9,786,000 |
| Q3 2019 | 14,085,000 | 11,469,000 |
| Q4 2019 | 8,400,000 | 7,540,000 |
| Q1 2020 | 2,354,000 | 2,357,000 |
| Q2 2020 | 2,045,000 | 1,198,000 |
| Q3 2020 | 595,000 | 1,713,000 |
| Q4 2020 | 4,770,000 | 1,346,000 |
| Q1 2021 | 3,333,000 | 911,000 |
| Q2 2021 | 2,425,000 | 1,925,000 |
| Q3 2021 | 5,999,000 | 838,000 |
| Q4 2021 | 2,842,000 | 3,950,000 |
| Q1 2022 | 5,368,000 | 3,995,000 |
| Q2 2022 | 1,541,000 | 2,359,000 |
| Q3 2022 | 2,156,000 | 2,792,000 |
| Q4 2022 | 980,616 | 7,134 |
| Q1 2023 | 36,000 | 0 |